Genentech: Eric Stefanich | Director and Senior Principal Scientist, Preclinical and Translational PKPD (PTPK)

Scientists / Our Scientists

"The path to longevity at Genentech involves having a strong mentor/role model, trusted network of colleagues, and exciting opportunities."

Years at Genentech

Publications at Genentech

I am a Senior Scientist and Group Leader in the PTPK group within Development Sciences. I am accountable for the pharmacology strategy from early stage research through first in human clinical trials for large molecule therapeutics in the areas of Immunology, Metabolic disease, Infectious disease, and Neurology.

Overall I have been at Genentech for over 21 years and have extensive drug development experience including writing regulatory documents as well as interactions with Health Authorities in US, Canada and Europe. I have also been team leader for the Pharmacology sub-team supporting several projects.

Featured Publication

A Humanized Monoclonal Antibody Targeting the Beta7 Integrin Selectively Blocks Intestinal Homing of T Lymphocytes.

Br J Pharmacol. 2011 Apr; 162(8): 1855–1870.

Stefanich EG, Danilenko DM, Wang H, O0Byrne S, Erickson R, Gelzleichter T, Hiraragi H, Chiu H, Ivelja S, Jeet S, Gadkari S, Hwang O, Fuh F, Looney C, Howell K, Albert V, Balazs M, Refino C, Fong S, Iyer S, Williams M.

View Abstract

Translational pharmacokinetics and pharmacodynamics of an FcRn-variant anti-CD4 monoclonal antibody from preclinical model to phase I study.

Clinical Pharmacology & Therapeutics, 2011; 89 (2):283-290.

Zheng Y, Scheerens H, Davis JC Jr, Deng R, Fischer SK, Woods C, Fielder PJ, Stefanich EG.

View Abstract

Therapeutic area lead for Immunology, Metabolic disease, Infectious disease, and Neurology. Accountable for translational pharmacology from early stage research through first in human clinical trials for large molecule therapeutics.

Pharmacology sub-team leader for Immunology and Cancer Immunotherapy related therapeutics. Accountable for nonclinical activities related to development of new therapeutics from Research through clinical development. Represent Development Sciences on the project core team and support key development decisions.

PK Scientist for Immunology and Cancer Immunotherapy related therapeutics on Pharmacology sub team. Supported selection of lead clinical candidate and project exposure-efficacy relationship based on preclinical disease models and projected human pharmacology. Supported toxicology studies and developed rationale for first inhuman dosing for new therapeutics. Wrote sections of regulatory filings for global Phase I studies and conducted pre-IND/CTA meetings with FDA, Canadian and European Health Authorities.

Performed due diligence on business development deals relating to PKPD and clinical dose and dose schedule.

Group leader of three Scientist and four Principal Scientific Researchers.

First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors

Clinical Cancer Research, ISSN: 15573265 10780432

Tae Won Kim; Howard A. Burris; Maria J. de Miguel Luken; Pishvaian; Bang; Michael S. Gordon; Ahmad Awada; D. Ross Camidge; F. Stephen Hodi; Grant A. McArthur; Miller; Andrés Cervantes; Laura Q.M. Chow; Alexander M. Lesokhin; Annemie Rutten; Mario Sznol; Deepali Rishipathak; Shang-Chiung Chen; Stefanich; Tony Pourmohamad; Maria Anderson; Jeong Kim; Mahrukh Huseni; Ina Rhee; Siu

Attention: This page may not render properly. The browser you are using, Internet Explorer 10, is no longer supported.

Eric Stefanich

Director and Senior Principal Scientist, Preclinical and Translational PKPD (PTPK)

Featured Publication

A Humanized Monoclonal Antibody Targeting the Beta7 Integrin Selectively Blocks Intestinal Homing of T Lymphocytes.

Translational pharmacokinetics and pharmacodynamics of an FcRn-variant anti-CD4 monoclonal antibody from preclinical model to phase I study.